ArticleBiomedicines2021
Serum Selenium Level and 10-Year Survival after Melanoma.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The Role of Vitamins and Micronutrients in the Prevention of Melanoma: A Review of Current Evidence.International journal of molecular sciences · 2026Review
- The Influence of Dietary Factors on Melanoma Development and Progression: A Comprehensive Review.Nutrients · 2025Review
- Beneficial Effects of Selenium and Its Supplementation on Carcinogenesis and the Use of Nanoselenium in the Treatment of Malignant Tumors.International journal of molecular sciences · 2024Review
- Evaluation of Selenium Concentrations in Patients with Crohn's Disease and Ulcerative Colitis.Biomedicines · 2024Article
- Blood and Serum Se and Zn Levels and 10-Year Survival of Patients after a Diagnosis of Kidney Cancer.Biomedicines · 2024Article
- Serum Selenium Concentration as a Potential Diagnostic Marker for Early-Stage Colorectal Cancer: A Comparative Study.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Correlation between Selenium and Zinc Levels and Survival among Prostate Cancer Patients.Nutrients · 2024Article
- Redox pathways in melanoma.Advances in cancer research · 2024Review
- Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study.Journal of translational medicine · 2023Article
- Serum Essential Elements and Survival after Cancer Diagnosis.Nutrients · 2023Article
- Autoimmunity to selenoprotein P predicts breast cancer recurrence.Redox biology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is one of the most aggressive human malignancies. The determination of prognostic biomarkers is important for the early detection of recurrence and for the enrollment of the patients into different treatment regimens. Herein, we report the 10-year survival of 375 melanoma patients depending on their serum selenium levels. The study group was followed up from the date of melanoma diagnosis until death or 2020. Patients were assigned to one of four categories, in accordance with the increasing selenium level (I-IV quartiles). The subgroup with low selenium levels had a significant lower survival rate in relation to patients with high selenium levels, HR = 8.42;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.